To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …

The past several months have witnessed the emergence of SARS-CoV-2 variants with novel
spike protein mutations that are influencing the epidemiological and clinical aspects of the …

The use of lipid-formulated RNA vaccines for cancer or COVID-19 is associated with dose-
limiting systemic inflammatory responses in humans that were not predicted from preclinical …

RNA vaccines are efficient preventive measures to combat the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) pandemic. High levels of neutralizing SARS-CoV-2 …

Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …

With the constantly mutating of SARS-CoV-2 and the emergence of Variants of Concern
(VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 …

Adjuvants are critical for improving the quality and magnitude of adaptive immune
responses to vaccination. Lipid nanoparticle (LNP)-encapsulated nucleoside-modified …

ABSTRACT Background SARS-CoV-2 mRNA vaccines have proven high efficacy, however,
limited data exists on the duration of immune responses and their relation to age and side …

Abstract SARS-CoV-2 mRNA-based vaccines are about 95% effective in preventing COVID-
19 1, 2, 3, 4, 5. The dynamics of antibody-secreting plasmablasts and germinal centre B …

Most COVID-19 vaccines are designed to elicit immune responses, ideally neutralizing
antibodies (NAbs), against the SARS-CoV-2 spike protein. Several vaccines, including …